Drug profile · INN
erdafitinib
BALVERSA
erdafitinib (BALVERSA) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — erdafitinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
erdafitinib (BALVERSA) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is erdafitinib?
erdafitinib (BALVERSA) is a fibroblast growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for erdafitinib?
BALVERSA is a marketed brand name for erdafitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erdafitinib?
erdafitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.